Supplier
Farmacia Doral, INC.
Farmacia Doral, INC. was paid $115.61M by Medicaid between Jan 2018 and Dec 2024, across 42 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 34% of everything it billed.
33Billing provider infoFARMACIA DORAL, INC.
SAN JUAN, PR 00926
SAN JUAN, PR 00926
33aNPI1003989831assigned 11/17/2006
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$115.61M
24GClaims82,396
24DCodes billed42
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Puerto Rico
Rank by total paid#1 of 32
Median peer was paid$500K
This provider vs. median231×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,320 | $7.26M | |
| 2019 | 12,819 | $11.24M | |
| 2020 | 16,560 | $18.45M | |
| 2021 | 13,506 | $17.61M | |
| 2022 | 12,153 | $19.83M | |
| 2023 | 8,630 | $18.75M | |
| 2024incomplete | 11,408 | $22.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 34% | 4,313 | 2,882 | $38.88M |
| J9035 | Injection, bevacizumab, 10 mg | 18% | 5,164 | 2,649 | $21.35M |
| J9299 | Injection, nivolumab, 1 mg | 13% | 2,026 | 1,286 | $15.23M |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 11% | 2,773 | 1,931 | $12.34M |
| J9306 | Injection, pertuzumab, 1 mg | 8.0% | 1,768 | 1,241 | $9.25M |
| J9312 | Injection, rituximab, 10 mg | 4.8% | 1,164 | 595 | $5.54M |
| J0897 | Injection, denosumab, 1 mg | 3.2% | 1,654 | 1,373 | $3.74M |
| J9395 | Injection, fulvestrant, 25 mg | 1.7% | 1,191 | 989 | $1.97M |
| J9055 | Injection, cetuximab, 10 mg | <1% | 170 | 98 | $1.10M |
| J9022 | Injection, atezolizumab, 10 mg | <1% | 158 | 103 | $992K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 250 | 168 | $955K |
| J9310 | Injection, rituximab, 100 mg | <1% | 199 | 85 | $636K |
30 more codes
| J9070 | Cyclophosphamide, 100 mg | <1% | 1,238 | $629K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 2,588 | $431K |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | <1% | 39 | $391K |
| J9171 | Injection, docetaxel, 1 mg | <1% | 1,637 | $359K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 3,997 | $277K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 51 | $263K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 2,075 | $183K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,019 | $173K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 206 | $172K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 4,257 | $162K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 78 | $90K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 2,630 | $87K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 1,812 | $81K |
| J9206 | Injection, irinotecan, 20 mg | <1% | 951 | $57K |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 950 | $40K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 17 | $39K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,924 | $37K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,540 | $36K |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | <1% | 16 | $27K |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 45 | $24K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,610 | $14K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 49 | $8K |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 189 | $8K |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 16 | $7K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | <1% | 28 | $6K |
| S0028 | Injection, famotidine, 20 mg | <1% | 6,170 | $6K |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 141 | $3K |
| J3490 | Unclassified drugs | <1% | 1,234 | $2K |
| J9370 | Vincristine sulfate, 1 mg | <1% | 17 | $152.19 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 42 | $134.06 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOLE, DEBRA (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Kroger Specialty Pharmacy FL 2 LLC | Orlando, FL | $1.32M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.